Myrtle Potter

Myrtle Potter has served as Chairman of the board of directors since August 2018. Ms. Potter has served as Chief Executive Officer of Sumitovant Biophama, Inc. since December 2019. Sumitovant Biopharma is a global biopharmaceutical company that is the parent to five biopharma companies. Formerly she served as Vant Operating Chair of Roivant Sciences from July 2018 to December 2019, where she oversaw a portfolio of thirteen biopharmaceutical companies and guided the initial public offerings of two. She founded Myrtle Potter & Company, LLC, a life sciences advisory firm, in September 2005 and served as the CEO until June 2018. She and her 100+ team of experts led major strategic efforts, including clinical development and product launch readiness efforts for numerous biopharmaceutical companies. Potter previously served as Chief Operating Officer, and later, President of Genentech, Inc. during a pivotal period of the company’s history. Under her leadership, Genentech achieved record sales and earnings growth for nineteen of twenty consecutive quarters. During this time, she was Co-Chair of the company’s Product Portfolio Committee that made all investment decisions for Genentech’s clinical development portfolio. Prior to Genentech, Potter was President of Bristol-Myers Squibb’s 3,500-person U.S. Cardiovascular and Metabolic business. Earlier she served at Merck where she founded and launched Astra/Merck, Inc. that today operates as AstraZeneca. Ms. Potter serves as Chairman of the Board of Myovant Sciences and serves on the boards of Liberty Mutual Holding Company and Axsome Therapeutics. She previously served on the boards of Amazon, Medco Health Solutions, Inc., Express Scripts Holding Co., Everyday Health, Inc, as well as numerous other public and private companies. Ms. Potter is a graduate of the University of Chicago where she is a Trustee.